Earlier this laboratory constructed a herpes simplex virus 1 recombinant (R5111) that carries a IL13 ligand inserted into glycoprotein D and can enter cells via the IL13Ra2 receptor commonly expressed on the surface of malignant glioma cells. In this report, we describe the properties of two recombinant viruses carrying chiemric gD genes. In R5181 recombinant virus the chimeric gene consisted on the residues 20-155 of urokinase plaminogen activator (uPA) inserted between residues 24 and 25 of gD. In R5182 the insert consisted of a 23-residue sequence encoding the uPA binding domain for the urokinase plaminogen activator receptor (uPAR). These viruses were constructed for three reasons, to increase the number of viruses that specifically target receptors on the surface of malignant glioma cells, to determine whether viruses exhibiting novel ligands could enter cells via receptors anchored to the cell surface via glycosylphosphatidylinositol anchor as has been recently demonstrated for nectin1, and to determine whether receptors other than IL13Ra2 could be targeted by genetic engineering of the virus. We report that R5181 but not R5182 recombinant virus was able to enter cells expressing uPAR. The results indicate that HSV-1 recombinant viruses can be engineered to enter cells via a variety of unrelated nonviral receptors, including receptors that are anchored to the cells surface but without transmembrane domains. Gene Therapy (2006) 13, 621-629.
Introduction
Clinical trials have established that it is possible to construct highly attenuated, replication competent herpes simplex virus 1 (HSV-1) mutants that are safe for delivery in amounts as high as 3 Â 10 9 PFU into human malignant gliomas in situ without adverse effects. 1, 2 The attenuation phenotype of these viruses is based on reduced ability to replicate in normal cells that are unable to supply adequate amounts of ribonucleotide reductase but are able to respond to the presence of complementary mRNAs by shutting down protein synthesis. The discrimination between the normal and malignant cells while impressive, is still short of optimal for selective destruction of cancer cells. To address this issue, this laboratory began studies designed to reconstruct the surface of the virion to reduce non-specific binding of virus particles to heparan sulfate and to provide ligands specific for receptors that are present exclusively or are enriched on the surface of cancer cells. The objective is to design viruses that are more robust than those currently in clinical trials but whose discriminating characteristic is based on affinity for specific cells surface receptors.
The entry of HSV into susceptible cells is a multi step event. On exposure to susceptible cells, HSV-1 glycoproteins B and C (gB and gC) bind to heparan sulfate. Another glycoprotein, gD interacts with one of two protein receptors, HveA or nectin1 (reviewed in Roizman and Knipe 3 ). The interaction of gD with its receptor activates fusogenic glycoproteins gB, gD and gL to fuse the envelope of the virus with the plasma membrane. The capsid is then released into the cytoplasm, transported to the nuclear core where it dumps its DNA into the nucleus. 3 In earlier studies, this laboratory reported the construction of a recombinant virus (R5111) capable of infecting cells via the IL13a2 receptor (IL13Ra2). 4 This receptor differs from the common IL13 receptor in that it does not signal, it is monomeric, contains a short cytoplasmic domain, does not interact with IL4 and in nature it is present in high-grade malignant gliomas or astrocytomas but also in human testes. In the R5111 recombinant the poly lysine tract responsible for the binding of gB to heparan sulfate was deleted, the amino terminal domain of gC was replaced with the corresponding domain of IL13 to abolish the interaction of gC with heparin sulfate as described in Laquerre et al., 5 and in addition the same domain of IL13 was inserted between amino-acids 24 and 25 of gD. Extensive studies have established that R5111 recombinant enters cells via the IL13Ra2 receptor and that it dos not depend on endocytosis as its primary mechanism of entry into cells. 6 We have undertaken the studies described in this report for three reasons. (i) A central issue was whether the construction of R5111 was a fortuitous selection of a 'compatible' ligand or whether the design we have employed could be applied to for construction of viruses with other affinities. (ii) As noted above, IL13Ra2 is a monomeric protein with a transmembrane and cytoplasmic domains. Not all receptors of potential interest contain transmembrane and cytoplasmic domains. Recently, it has been shown that HSV can enter cells via nectin1 receptor anchored to cell surface via a glycosylphosphatidylinositol anchor. 7 A central question is whether viruses incorporating novel ligands could also enter cells via receptors anchored at the cell surface and lacking transmembrane domains. (iii) Lastly, it was of interest to increase the number and range of viruses capable of infecting malignant glioma cells via a specific receptor. We selected to target the HSV-1 to malignant glioma cells by inserting into gD a ligand for the human uPAR reported to be highly expressed in malignant gliomas. 8, 9 uPAR is a 335 residue protein attached to the cell surface via a glycosylphosphatidylinositol anchor. It lacks transmembrane and cytosolic domains. uPAR binds and localizes the urokinase plasminogen activation (uPA) at the cell surface. 10 Increased uPA activity has been reported in malignant astrocytomas in vitro and in malignant brain tumors in vivo. In malignant brain tumors uPA activity was correlated with poor prognosis. Increased cell surface uPA activity facilitates cellular movement via extracellular matrix (ECM) degradation, which is necessary for tumor cell invasion, chemotaxis, and cellular adhesion. 11, 12 In the studies reported here, we constructed two recombinant viruses. In R5181 the amino terminal peptide of comprising amino-acids 20-155 of uPA was inserted between amino acids 24 and 25 of gD. This peptide is approximately the same size as the portion of IL13 inserted into gD at the same position in R5111 recombinant virus. In recombinant virus R5182 we inserted a peptide containing residues 34-57 of uPA. This peptide contains the binding site of uPA for uPAR. We report that R5181 rcombinant virus infected cells carrying uPAR in a receptor dependent fashion whereas R5182 mutant did not.
Materials and methods

Cells and viruses
Vero cells were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's modification of Eagle minimal essential medium (DMEM) supplemented with 5% newborn calf serum (NBSC). Rabbit skin cells were originally obtained by J McLaren and maintained in DMEM supplemented with 5% NBSC. J1.1, a derivative of BHK, and thymidine kinase minus cells that lack both HveA and nectin 1 receptors was a kind of gift from G Campadelli-Fiume (University of Bologna, Italy). J-HveA, J-Nectin cell line, which expressed HveA and Nectin, respectively, in J1.1 cells were provided by Dr G Campadelli-Fiume too.
The gDÀ/À mutant lacks both the gD gene and the gD protein in its envelope. It is produced by infection of cells lacking the complementing gD gene with a mutant virus stock (gDÀ/+) produced in complementing cells. The procedure for the production and tritration of gDÀ/À virus was described elsewhere. 13 gDÀ/À virus enters cells by endocytosis and at high multiplicities in the absence of complementing gD is cases cells to undergo apoptosis. 13 
Plasmids
The plasmids containing a scu-uPA cDNA, pULscuPA, was a kind of gift Dr DA Dichek (University of Washington Medical Center).
14 The plasmids containing a human uPAR cDNA were kindly provided by Dr HA Chapman (University of California, San Francisco, CA). 15 
Antibodies
Monoclonal antibodies against gD (clone H170) or ICP0 (clone H1083) described elsewhere were purchased from the Goodwin Institute, Plantation, FL. Monoclonal antibodies against U S 11 protein were described previously. 16 Monoclonal antibodies against human-uPAR and human ATF of uPA were purchased from R&D Systems Inc. (Minneapolis, MN) and American Diagnostica Inc. (Stamford, CT), respectively.
Construction of the ATF-uPA-gD plasmids
The complete cDNA of amino-terminal fragment (ATF) of uPA without the N-terminal signal peptide was amplification from pULscuPA plasmid by two primers ATF-uPA-XhoI, 5
0 -CCGCTCGAAGCAATGAACTTCATC AAGTTCCATC-3 0 and ATF-uPA-KpnI 5 0 -GGGGTACCTT TTCCATCTGCGCAGTCATGCACC-3 0 . The PCR product was gel purified and ligated into pGEM-T Easy Vector (Promega, Madison, WI). The sequence of ATF-uPA was verified by sequencing of the entire ATF. Plasmid pGG5112 carries a 3648 bp fragment containing gD, mutant IL-13(E13Y) and flanking sequences in the EcoRI/XbaI site of pBR322. 6 To construct the ATF-uPAgD chimeric plasmid, pGG5112 was digested with XhoI and KpnI to release two fragments, 6.2 and 0.4 kb, respectively. Plasmid ATF-uPA-gD was digested with XhoI and KpnI and then inserted into the XhoI and KpnI site of the 6.2-kb fragment to generate the ATF-uPA-gD chimeric transfer plasmid.
Construction of the R5181 (ATF-uPA-gD) and R5182 (BD-uPA-gD) recombinant viruses The R5181 and R5182 recombinant viruses were generated by cotransfection of transfer plasmid ATF-uPA-gD or BD-uPA-gD and the R5110 viral DNA into rabbit skin cells by Lipofectamine reagent (Life Technologies, Grand Island, NY), respectively. The progeny of the transfection was plated at a high dilution on Vero cell cultures so as to yield individual, well-spaced plaques. From each of the infected cell cultures, four single plaques were picked, frozen-thawed, sonicated, and then replated for preparation of virus stocks and viral DNA for sequencing on fresh cultures of Vero cells.
Viral DNA extraction
The infected cells were removed from each of the 25-cm 2 flasks exposed to the individual plaque isolates, rinsed, and resuspended in 500 ml of Lyse-O-Lot (150 mM NaCl/ Recombinant virions exhibiting the amino terminal fragment H Kamiyama et al 10 mM Tris/1.5 mM MgCl 2 ) in the presence of 0.1% of Nonidet P-40. The nuclei were removed by low-speed centrifugation. SDS to 0.2%, EDTA to 5 mM, and b-ME to 50 mM were added to the supernatant fluid, which was then extracted twice with phenol/chloroform. Viral DNA was finally precipitated by ethanol and resuspended, and the ATF-uPA-gD or BD-uPA-gD chimeric reading frame were amplified by PCR with a sets of primers. The set designed to detect ATF-uPA-gD or BD-uPA-gD consisted of 5 0 -CGGAATTCGATGGGGGGGGCTGCCG CCAG-3 0 and 5 0 -AACTGCAGCTAGTAAAACAAGGGC TGGTGCG-3 0 . The gD PCR products were sequenced to determine whether the gD and ATF-uPA, or BD-uPA sequence contained deletions or substitutions.
Construction of J-uPAR, a Cell Line Stably Expressing human uPAR
J1.1 cells stably transfected with the human uPAR expression plasmids by using Lipofectamine kit (GIB-CO/BRL) were selected on the basis of their resistance to hygromycin B (Invitrogen, Carlsbad, CA). Hygromycin B-resistant clones were amplified and screened for uPAR expression by immunoblotting with monoclonal antihuman uPAR antibody. Thus, parental and transformed cells solubilized in SDS, where each was electrophoretically separated in a denaturing gel (100 mg/lane), transferred to a nitrocellulose sheet, and probed with antibody against uPAR followed by appropriate secondary antibody conjugated to alkaline phosphatase (Bio-Rad). The protein bands were visualized with 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (Denville Scientific, Metuchen, NJ). One (J-uPAR-7) was selected for the experiments described below.
Cell surfaces immunostaining
Hygromycin B-resistant cells (J-uPAR) in 25-cm 2 fasks were removed from the dish by gentle scrap and reacted with human uPAR antibodies (5 mg/ml) for 15 min on ice. The cells were then rinsed with cold PBS and reacted for 15 min with 1:64 dilution of a goat anti-mouse immunoglobulin G conjugated to fluorescein isothiocyanate (FITC) (Sigma, St Louis, MO) in ice-cold PBS. After rinsing with cold PBS, the cells were suspended in 100 ml of ice-cold PBS for further immunofluorescence analyses. The surface-stained cells (10 ml) were plated onto fourwell glass slides and mounted in 90% glycerol. Slides were analyzed with the aid of a Zeiss confocal microscope. A total of 200 cells in adjacent fields were examined for surface fluorescence.
Virus titration
Replicate cultures of J-uPAR, J1.1, J-HveA and J-Nectin were exposed to 0.1 PFU of R5181, R5182, or HSV-1(F) virus per cell. After 24 h of incubation, the cells were harvested, sonicated and titrated on Vero cell.
Immunoblotting electrophoretically separated proteins
The indicated cells were mock-infected or exposed to 10 PFU of recombinant or wild-type HSV-1(F) per cell. The cells were harvested 24 h after infection, disrupted in SDS disruption buffer, boiled, cleared by centrifugation, electrophoretically separated on a 10% denaturing polyacrylamide gel, transferred onto a nitrocellulose membrane, and reacted with antibodies as indicated in results according to procedures described elsewhere. 13 
Inhibition of virus entry via endocytic pathway
Cells were exposed to Bafilomycin (Sigma, 0.1 U/ml) or to freshly prepared NH 4 Cl at indicated concentrations for 30 min at 371C and then exposed to R5181 recombinant virus or HSV-1(F) in the presence of the drugs. After 24 h of incubation, the cells were harvested, sonicated and titrated on Vero cell.
Phosphatidyl inositol-specific phospholypase C (PI-PLC) digestion of cultured cells Cells were exposed to 0.1 U/ml of PI-PLC from Bacillus cereus (Sigma) in PBS. After 1 h of incubation at 371C, cells were exposed to 0.1 PFU of R5181 recombinant virus or HSV-1(F) per cell. After 24 h of incubation the viruses were harvested and titrated on Vero cell.
Isolation and reverse transcription of RNA extracted from J1.1 and J-uPAR cells Total RNA was extracted with the aid of TRIzol reagent according to the manufacturer's instructions (Life Technologies, Rockville, MD). DNase I treatment instructions (Life Technologies), phenol/chloroform extraction, and ethanol precipitation (Fisher Scientific, Houston, TX) were carried out to remove possible DNA contamination. Total RNA (3 ml) was reverse transcribed to yield singlestranded cDNA with 20 U of AMV (Promega) in a total reaction volume of 30 ml. The reverse transcription was primed with the primer: human uPAR reverse 5 0 -GG CAGTCATTAGCAGGGTGATGGTG-3 0 or hamster uPAR reverse 5 0 -GTTGCCCTCGCAGCTGTAACACTGG-3 0 and performed using a pool of nucleotides consisted of 10 mM concentrations (each) of dGTP, dATP, dTTP, and dCTP (Promega). In all, 40 U of RNasin (Promega) were added to each reaction mixture. The mixture containing only the RNA template, and the primer was first heated at 701C for 10 min, chilled on ice, and after the addition of the other components, incubated at 421C for 30 min, shifted at 521C for 30 min, and then heat inactivated at 951C for 5 min. cDNAs obtained from reverse transcription of RNA extracted from J1.1 and J-uPAR cells were amplified by PCR under the following conditions: 1 min at 941C, 1 min at 601C, and 1 min 15 s at 721C. The following primers were used for PCR; uPAR-start forward: 5 0 -ATGGGTCACCCGCCGCTGCTGCCGC-3 0 and human uPAR reverse or hamster uPAR reverse primer as described above.
Human scuPA competition assay
Human single chain uPA (scuPA) were purchased from American Diagnostica Inc. (Stamford, CT). Cells were exposed to increasing concentrations of the human scuPA for 60 min at 371C and then exposed to 0.1 PFU of R5181 recombinant virus for 120 min at 371C in the presence of the human scuPA. After 24 h of incubation, the cells were harvested, sonicated and titrated on Vero cell.
Results
Verification of the Structure of R5181 and R5182 recombinant viruses
The structure of the chimeric gD in R5181 and R5182 recombinant viruses is depicted in Figure 1 and detailed 
Transfection and selection of the J-uPAR cell line
To test whether R5181 recombinant and R5182 viruses were able to use human uPAR protein as a receptor for entry, we constructed in parallel a cell line expressing this protein in the absence of other HSV-1 entry receptors. The properties of the J1.1 cell line were published elsewhere. 4 In essence, this cell line lacks the receptors necessary for the entry of virus into cells, and is not susceptible to infection by wild-type virus. The transfection of J1.1 cells with the plasmid encoding the human uPAR protein, and selection of the cell line expressing the protein are detailed in Materials and methods. To test for the production of human uPAR protein, 14 clones of the selected cells were harvested, solubilized, subjected to electrophoresis in denaturing polyacrylamide gels, and tested for the expression of the protein. As shown in Figure 4 , all clones expressed a protein reactive with the anti-human uPAR antibody but differed in the level of expression. The apparent size of the protein was consistent with the reported size of uPAR. Of 14 J-uPAR-positive clones, J-uPAR-7 ( Figure 4 , lane 8) was selected for further studies because of the highest expression level of uPAR.
Properties of J-uPAR cell line
uPAR is anchored to the plasma membrane through the glycosylphosphatidylinositol and lacks transmembrane and cytosolic domains. In light of our experience with the cells carrying the IL13a2 receptor, 6 we investigated the expression of uPAR in the selected cell line using immunoflueoresce as the detection method for uPAR. In the first series of experiments, we found that 70% of the J-uPAR In the second series of experiments, we investigated the effect of fetal bovine serum (FBS) on the expression of uPAR since components of FBS could internalize cell surface receptors as was the case for IL13Ra2. 6 J-uPAR cells were grown in serum-free and specialty medium (AIM-V Medium, Invitrogen, Carlsbad, CA) containing different concentration of FBS and examined the expression of uPAR and other properties. FBS affected the signal intensity but not the percentage of positive cells. Thus the signal intensity was strongest at 0% FBS and progressively decreased to a low level in 10% FBS whereas the number of positive cells remained relatively steady (90 at 0% FBS compared to 83 for 10% FBS). Cells grown in AIM-V medium in the absence of serum grew poorly. Moreover, the cells could not be serially passaged. The results indicated that FBS negatively affected the presence of uPAR on the cell surface but that at least a low concentration of FBS was needed to maintain J-uPAR cells.
Growth properties of R5181 and R5182 recombinant viruses
Replicate cultures of J-uPAR, J1.1, J-HveA and J-Nectin were exposed to 0.1 PFU of R5181, R5182 or HSV-1(F) per cell. After 24 h of incubation, the cells were harvested 
R5181 recombinant virus enters J1.1 cells via an endogenous uPA receptor
The experiments described above indicated that R5181 virus replicated in the J1.1 cells. One possible explanation for these results is that J1.1 cells express an endogenous hamster uPAR. Consistent with this hypothesis is the evidence reported elsewhere that human uPA binds to hamster uPAR with high affinity. 17 To test this hypothesis, two series of experiments were carried out. In the first, we tested whether J1.1 cells express hamster uPAR mRNA. The procedures for amplification of uPAR mRNA with human or hamster-specific primers was as described in Materials and methods. As shown in Figure 6 , the J1.1 cell line contained detectable levels of hamster uPAR mRNA but not the human uPAR mRNA.
In the second series of experiments we used human single chain uPA (scuPA) to compete with the virus for the putative hamster uPA receptor on J1.1 cells. The J1.1 cells were exposed to increasing concentrations of the human scuPA for 60 min at 371C and then exposed to R5181 recombinant virus (0.1 PFU/cell) for 120 min at 371C in the presence of the human scuPA. After 24 h of incubation, the cells were harvested, sonicated and titrated on Vero cell. Earlier studies showed that human scuPA binds to human uPAR with high affinity (Kd of about 1 nM) 18, 19 and that human scuPA binds to hamster uPAR with the same affinity as for the human receptor (Kd ¼ 1.1 nM) . 17 The J1.1 cells exposed to highest concentration of scuPA produced 10-fold less virus than control untreated cells (Figure 7) . The results (Figure 7) show that scuPA competed with the virus more successfully in J1.1 cells than in J-uPAR cells consistent with the expectation that J-uPAR cells would have more receptors than J1.1 cells. 
Recombinant virions exhibiting the amino terminal fragment H Kamiyama et al
Entry of R5181 into J-uPAR or J1.1 cells is blocked removal of uPAR with PI-PLC digestion uPAR is bund to the cell surface via a glycosylphosphatidylinositol anchor. 20, 21 The further test the hypothesis that R5181 recombinant virus enters cells via its interaction with uPAR, we exposed the cells to PI-PLC as described in Materials and methods. The expectation was that if the virus enters the cells via uPAR, removal of uPAR by digestion of cell surface glycosylphosphatidylinositol anchor with PI-PLC would block virus entry. As shown in Figure 8 , PI-PCL digestion had no effect on wild-type virus virus entry into J-HveA or J-Nectin cells or the entry of R5181 recombinant virus R5181 recombinant virus enters J-uPAR cells by a mechanism independent of endocytosis Two series of experiments were one to determine whether R5181 recombinant virus enters cells by endocytosis. In the first series, we tested whether the replication of R5181 recombinant virus was inhibited by NH 4 Cl -an inhibitor of endosome acidification. In this series, the cells were pretreated with the increasing concentrations of NH 4 Cl for 30 min and then exposed to R5181 or wild-type HSV-1(F) virus. After 24 h of incubation, the cells were harvested, sonicated and titrated on Vero cell. The entry of R5181 recombinant virus into J-uPAR or J1.1 cells was not inhibited by NH 4 Cl even at the highest concentration tested ( Figure 9 ). In the second series of experiments, we tested the effects of Bafilomycin -a more specific inhibitor for endosomes acidification. 7 The protocol for these experiments was similar to that used for the studies on the entry of the R5111 mutant in cells expressing IL13Ra2. 6 To test whether Bafilomycin was effective in J1.1 and derivative cells, J-Nectin cells were transduced with baculoviruses encoding glycoprotein D and incubated for 6 h. Then the cells were then either left untreated or exposed for 1 h to 0.1 units of Bafilomycin (Figure 10) . The cells were then infected with 0.1 PFU of gDÀ/À mutant per cells. As reported earlier gDÀ/À virus enters cells by endocytosis and in cells lacking the gD genes the virus causes apoptosis. 6, 13 The expectation was that the gDÀ/À virus would enter cells by endocytosis, and that the gD produced in transduced cells would block cells from undergoing apoptosis and enable the synthesis of gDÀ/+ virus. The results of the control experiment shown in Figure 10a indicated that Bafilomycin suppressed the replication of gDÀ/+ virus and hence inhibited endocytosis of gDÀ/À virus. In the second part of the experiment, the same treatment did not block the entry and replication of HSV-1(F) into cells expressing HveA or nectin 1 or the entry and replication of R5181 recombinant virus in J1.1 or J-uPAR cells ( Figure  10b) . The results indicate that the wild-type or mutant viruses do not depend on endocytosis for entry and replication.
Discussion
In this report, we describe the construction and some properties of recombinant viruses designed to target cells expressing uPAR. As note in the introduction, the objectives of this study was three-fold, that is, to determine whether the design applied to target IL13Ra2 receptor could be applied to other receptors, to target a cell surface protein without a transmembrane or a cytplasmic domain, and finally, to increase the repertoire of viruses that specifically target protein prevalent on the surface of malignant glioma cells.
The salient features of our results are as follows: Figure 9 The Effect of NH 4 Cl. on R5181 virus infectivity in J-uPAR and J1.1. Cells grown in 25-cm 2 flasks were exposed to increasing concentrations of NH 4 Cl. After for 30 min of incubation at 371C, the cells were exposed to 0.1 PFU of recombinant virus or HSV-1(F) per cell for 120 min in the same medium. The cells were harvested 24 h after infection. Progeny virus was titered on Vero cells.
Recombinant virions exhibiting the amino terminal fragment H Kamiyama et al replication is less efficient than that of R5111 virus, which targets the IL13Ra2 receptor. In R5182, we inserted a much smaller peptide of 24 residues consisting of the binding site of uPA for uPAR. We found no evidence that this virus is able to infect cells via uPAR. At this time, we do not know whether the R5182 virus failed to infect cells via uPAR because the secondary structure of the chimeric gD blocked the binding site from interacting with uPAR or whether the insert was incompatible with the predicted modification of gD following its interaction with a receptor.
(ii) Several lines of evidence indicate that R5181 recombinant virus enters J1.1 cells by interacting with uPAR. Thus (a) scuPA competed with the virus for entry into J1.1 cells (b) removal of uPAR via a glycosylphosphatidyl inositol with PI-PLC blocked entry of mutant virus into J1.1 or J-uPAR cells but had no effect on entry of wild-type virus via natural receptors of the mutant virus into J-nectin cells.
(c) Studies with two different types of endocytosis inhibitors excluded the possibility that the mutant virus enters cells via endocytosis. It is of interest to note that NH 4 Cl reduced the already low yield of HSV-1(F) in J-uPAR or J1.1 cells by approximately 10-fold. This finding is consistent with the hypothesis that a small amount of virus may enter cells by endocytosis in the absence of a specific receptor. (iii) Although this study began with the premise that BHK TK-cell would not exhibit an uPA receptor, the results demonstrated a rather interesting phenomenon that bears on the selection of receptors for further studies. In this and preceding studies, 6 we found that cells transduced with either IL13Ra2 or uPAR required special care in the maintenance of the receptor on serial passage. The stability of the receptor was dependent on cell type, serum concentration and as in the studies described here, the method by which the cells were dislodged for serial passage. Yet BHK TK-cells have been passaged numerous times by a variety of means and they still express the endogenous receptor albeit at levels significantly lower than that that of transduced cells. The lessons to be learned from this and preceding studies 6 is that receptors may not always be present in tumors passaged serially in culture or they may be unstable in transduced cells. (iv) A key finding presented in this report is that ligands other that IL13 may be inserted into the HSV-1 virion to provide a mode of entry into cells. We also show that ligands may be targeted to receptors that are not anchored via their own transmembrane domain consistent with the recent report that wildtype HSV can enter cells via nectin1 receptor anchored to the cell surface by glycosylphosphatidylinositol. Lastly, we have constructed an additional virus that targets a receptor commonly found on malignant gliomas. Recombinant virions exhibiting the amino terminal fragment H Kamiyama et al
